Market Overview - On September 25, the Tianjin state-owned enterprise reform sector fell by 0.72% compared to the previous trading day, with Jintou Chengkai leading the decline [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - The following stocks in the Tianjin state-owned enterprise reform sector showed notable performance: - Baili Electric (600468) closed at 6.73, up 4.02% with a trading volume of 1.021 million shares and a turnover of 693 million yuan [1] - Jintou Chengkai (600322) closed at 2.35, down 6.37% with a trading volume of 868,900 shares and a turnover of 210 million yuan [2] - Other stocks such as Tianjin Port (600717) and Taida Co. (000652) also experienced declines of 1.28% and 1.45% respectively [1][2] Capital Flow Analysis - The Tianjin state-owned enterprise reform sector saw a net outflow of 38.27 million yuan from main funds, while speculative funds had a net inflow of 53.41 million yuan, and retail investors experienced a net outflow of 15.13 million yuan [2] - Specific stock capital flows included: - Baili Electric had a net inflow of 20.84 million yuan from main funds, while retail investors saw a net outflow of 4.25 million yuan [3] - Tianjin Port had a net inflow of 9.34 million yuan from speculative funds, but a net outflow of 9.81 million yuan from retail investors [3]

证券日报网讯力生制药（002393）9月18日在互动平台回答投资者提问时表示，截至2025年9月10日公司 股东户数为25376户。 ...

格隆汇9月18日丨力生制药(002393.SZ)在投资者互动平台表示，公司目前暂无治疗该病症的药物。 ...

Group 1 - On September 17, Lisheng Pharmaceutical's stock fell by 1.20%, with a trading volume of 87.40 million yuan [1] - The financing data shows that on the same day, Lisheng Pharmaceutical had a financing purchase amount of 8.10 million yuan and a financing repayment of 16.16 million yuan, resulting in a net financing outflow of 8.06 million yuan [1] - As of September 17, the total balance of margin trading for Lisheng Pharmaceutical was 310 million yuan, accounting for 5.21% of its circulating market value, which is above the 90th percentile of the past year [1] Group 2 - As of August 20, the number of shareholders of Lisheng Pharmaceutical was 31,200, a decrease of 0.39% from the previous period, while the average circulating shares per person increased by 0.39% to 8,017 shares [2] - For the first half of 2025, Lisheng Pharmaceutical achieved an operating income of 732 million yuan, a year-on-year decrease of 1.76%, while the net profit attributable to the parent company was 343 million yuan, a year-on-year increase of 235.04% [2] Group 3 - Since its A-share listing, Lisheng Pharmaceutical has distributed a total of 1.261 billion yuan in dividends, with 255 million yuan distributed in the last three years [3] - As of June 30, 2025, Dazheng Jingheng Mixed A (090019) has exited the list of the top ten circulating shareholders of Lisheng Pharmaceutical [3]

Core Viewpoint - The stock price of Lifesun Pharmaceutical has shown significant fluctuations, with a year-to-date increase of 41.51% and recent declines in the short term, indicating potential volatility in investor sentiment and market performance [2]. Group 1: Stock Performance - As of September 12, Lifesun Pharmaceutical's stock rose by 2.04%, reaching 24.47 CNY per share, with a total market capitalization of 6.306 billion CNY [1]. - The stock has experienced a 1.09% decline over the last five trading days and a 3.24% decline over the last 20 days, while showing a 26.98% increase over the last 60 days [2]. Group 2: Financial Metrics - For the first half of 2025, Lifesun Pharmaceutical reported a revenue of 732 million CNY, a year-on-year decrease of 1.76%, while the net profit attributable to shareholders increased by 235.04% to 343 million CNY [3]. - The company has distributed a total of 1.261 billion CNY in dividends since its A-share listing, with 255 million CNY distributed over the last three years [4]. Group 3: Shareholder Information - As of August 20, the number of shareholders for Lifesun Pharmaceutical was 31,200, reflecting a decrease of 0.39% from the previous period, while the average number of tradable shares per shareholder increased by 0.39% to 8,017 shares [3]. - The top ten circulating shareholders saw a change, with Dazheng Jingheng Mixed A exiting the list as of June 30, 2025 [4]. Group 4: Business Overview - Lifesun Pharmaceutical, established on June 17, 1981, and listed on April 23, 2010, is primarily engaged in the production and sales of various pharmaceutical products, including tablets (59.92% of revenue), injections (15.69%), and capsules (8.75%) [2]. - The company operates within the pharmaceutical and biological sector, specifically in chemical pharmaceuticals and formulations, and is associated with concepts such as heparin and vitamins [2].

与投资者同行 为价值共筑——天津辖区上市公司2025年投资者网上集体接待日暨半年报业绩说明会9月 11日在全景网举行。力生制药（002393）（002393）独立董事方建新介绍，原料制剂协同降本，力生制 药深入推进原料药与制剂一体化发展。通过自行研发原料药，降低生产成本，从而缓冲集采降价冲击。 公司积极拓展销售覆盖广度与深度。对于中标集采品种，凭借企业品牌优势与销售网络，努力扩大基层 医疗、零售药店等多元渠道铺货量，以更广泛的市场触达，深挖市场，增加销量。 ...

Core Insights - The event held on September 11 focused on the performance explanation of Tianjin-listed companies and highlighted the achievements of Lifesun Pharmaceutical in drug development since 2020 [1] Company Developments - Lifesun Pharmaceutical has made significant progress in new product research and development, with multiple drug approvals achieved [1] - The company has received drug registration certificates for 13 generic products, including Valsartan Amlodipine and Rivaroxaban tablets [1] - A total of 22 product specifications have passed consistency evaluations, and 9 chemical raw material drug applications have been approved [1] Market Strategy - The company aims to enrich its product structure and enhance its marketing system, leading to increased product sales and market share [1] - Lifesun Pharmaceutical is committed to deepening the synergy between research and industrialization to provide accessible quality medications for patients while creating long-term value for investors [1]

Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing up to RMB 600 million for purchasing short-term financial products with high safety and liquidity, ensuring it does not affect the implementation of investment projects [1] Group 1: Cash Management Details - The company has invested a total of RMB 70 million in structured deposits at Industrial Bank Co., Ltd. Tianjin Branch [1] - There is no related party relationship between the company and Industrial Bank [1] Group 2: Risk Control Measures - The company aims to control risks by purchasing short-term financial products that are safe and liquid, issued by major commercial banks or securities institutions [3] - The finance department is responsible for managing the purchased financial products and will take timely measures if any risk factors affecting fund safety are identified [3] - The audit department will regularly audit the use and custody of the purchased financial products and report to the board and supervisory committee [3] Group 3: Impact on the Company - The company emphasizes compliance and effective control of investment risks while using idle raised funds for cash management, which will not affect daily operations or the normal progress of investment projects [4] - This cash management approach is expected to improve the efficiency of fund usage and generate investment returns for the company and its shareholders [4] Group 4: Previous Cash Management Activities - As of the announcement date, the total amount of idle raised funds used for cash management that are not yet due is RMB 155 million, which is within the approved limits [4]

Core Viewpoint - Tianjin Development (00882) announced a partnership agreement involving its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical, to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1: Fund Structure and Investment Focus - The fund will primarily invest in equity of unlisted companies and/or stocks issued or traded in a non-public manner by listed companies, focusing on the health and biotechnology sectors in China, including innovative drugs, medical devices, and related services [1] - Lifescience Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund [1] Group 2: Risk Management and Investment Strategy - By participating in the fund, Lifescience Pharmaceutical's cost risk is limited to its subscribed amount, avoiding additional expenses and debts compared to direct investments [2] - The fund's investment decisions require approval from the investment decision committee, ensuring that decisions are made with the consent of both Jianxin Equity and Teda Private Equity [2] Group 3: Strategic Benefits and Long-term Outlook - Participation in the fund will enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [3] - The investment is expected to provide opportunities for mergers and acquisitions aligned with the company's strategic goals, improve capital allocation efficiency, and enhance the company's sustainable operational capabilities [3]

Core Viewpoint - Tianjin Development (00882) announced a partnership agreement involving its indirect subsidiary, Lifespring Pharmaceutical (002393), to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1: Fund Structure and Investment Focus - The fund will primarily invest in equity of unlisted companies and/or stocks issued or traded in a non-public manner by listed companies, focusing on the health and biotechnology sectors in China, including innovative drugs, medical devices, and related services [1] - Lifespring Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund [1] Group 2: Risk Management and Investment Strategy - By participating in the fund, Lifespring Pharmaceutical's cost risk is limited to its subscribed amount, avoiding additional expenses and debts compared to direct investments [2] - The fund's investments require approval from the investment decision committee, ensuring that decisions are made with the consent of both Jianxin Equity and Taida Private Equity [2] Group 3: Strategic Benefits and Long-term Outlook - Participation in the fund will enhance the group's understanding of the latest industry developments, diversify investment risks, and identify potential strategic partners for future opportunities [3] - The investment is expected to provide opportunities for industry mergers and acquisitions aligned with the company's strategic development, improving capital allocation efficiency and enhancing sustainable operational capabilities [3]